Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

The Food Safety and Standards Authority of India (FSSAI) has floated a consultation paper seeking comments from stakeholders on compliance issues related to analogue dairy products. The paper ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

including more familiarity with the incretin therapies by the time of tirzepatide approval.” And, Galindo added, tirzepatide generally has been shown to have higher glucose-lowering potency than ...